reports
Macrogenics Inc: 1 director
A director at Macrogenics Inc sold after exercising options/sold 51,395 shares at 15.549USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data ...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data, including safety and preliminary efficacy, by May 31Company plans to provide additional clinical data – including rPFS – in the Fall of 2024 ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, devel...
Autoscope Technologies Corporation Announces Financial Results
Autoscope Technologies Corporation Announces Financial Results MINNEAPOLIS, March 21, 2024 (GLOBE NEWSWIRE) -- Autoscope Technologies Corporation (OTCQX: AATC) today announced results for its quarter and year ended December 31, 2023. Fourth Quarter 2023 Financial Summary Royalties increased 5 percent to $2.5 million compared to $2.4 million in the same period in the prior year.Product sales increased 219 percent to $102,000 compared to $32,000 in the same period in the prior year.Operating expenses from continuing operations were comparable at $2.0 million in the fourth quarter ...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financia...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from Recent Financing Extends Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a...
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Precl...
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease Tenaya Anticipates Dosing First Patient in Phase 1b RIDGE™-1 Clinical Trial of TN-401 in Second Half of 2024 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya The...
MacroGenics Provides Update on Corporate Progress and 2023 Financial R...
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADCPreclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, to be presented in posters at AACRConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on di...
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2024: TD Cowen’s 44th Annual Health Care Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a Prostate Ca...
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Co...
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March ...
Tenaya Therapeutics to Participate in Upcoming March Investor Conferen...
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows: TD Cowen 44th Annual Health ConferenceForm...
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibit...
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone or in Combination with SGLT2 Inhibitor in Murine Models of Disease SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the unde...
Autoscope Technologies Corporation Announces Dividend
Autoscope Technologies Corporation Announces Dividend MINNEAPOLIS, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Autoscope Technologies Corporation (“Autoscope”) (OTCQX: AATC) announced today that its Board of Directors has declared a regular quarterly dividend of $0.13 per share of common stock, payable on March 5, 2024 to shareholders of record at the close of business on February 27, 2024. About Autoscope Technologies Corporation Autoscope Technologies Corporation is a global company dedicated to helping improve safety and efficiency for cities and highways by developing and delivering above-gro...
- Jonathan Moreland
Tenaya Therapeutics Announces Pricing of Underwritten Offering
Tenaya Therapeutics Announces Pricing of Underwritten Offering SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 2,222,271 shar...
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference (New York). MacroGenics’ President and CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on ...
Autoscope Technologies Corporation Announces a $1.32 Per Share Special...
Autoscope Technologies Corporation Announces a $1.32 Per Share Special Cash Dividend MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Autoscope Technologies Corporation (“Autoscope”) (OTCQX: AATC) announced today that its Board of Directors has declared a special one-time cash dividend of $1.32 per share of common stock, payable on February 12, 2024 to shareholders of record at the close of February 5, 2024. As a result of the Board's review of the Company's current financial position and business outlook, the Board determined that the payment of a special dividend was in the best interest...
Autoscope Technologies Corporation Announces 2024 Annual Meeting of Sh...
Autoscope Technologies Corporation Announces 2024 Annual Meeting of Shareholders MINNEAPOLIS, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Autoscope Technologies Corporation (“Autoscope”) (OTCQX: AATC) today announced today that its Board of Directors will be holding the 2024 Annual Meeting of Shareholders on Thursday, February 8, 2024 at 10:00 a.m., Central Time. The annual meeting will be a completely virtual meeting of shareholders, which will be conducted via the Internet. The Board of Directors has fixed the close of business on January 17, 2024, as the record date for the determination of shar...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
USB U.S. BANCORP
VNO VORNADO REALTY TRUST
VKTX VIKING THERAPEUTICS
TXN TEXAS INSTRUMENTS INCORPORATED
SMCI SUPER MICRO COMPUTER INC.
RMBS RAMBUS INC.
QCOM QUALCOMM INC
PYPL PAYPAL HOLDINGS INC
PSTG PURE STORAGE INC. CLASS A
PEB PEBBLEBROOK HOTEL TRUST
NVMI NOVA MEASURING INSTRUMENTS LTD
NVDA NVIDIA CORPORATION
MGNX MACROGENICS INC.
FORM FORMFACTOR INC.
FAN FABRINET
FFWM FIRST FOUNDATION
APEI AMERICAN PUBLIC EDUCATION
ALLY ALLY FINANCIAL INC
ACU ACME UNITED CORP.
ELTK ELTEK
BKD BANGKOK DEC-CON
KLAC KLA CORPORATION
PLAB PHOTRONICS INC.
FLXS FLEXSTEEL INDUSTRIES INC.
MRUS MERUS B V
ATGE ADTALEM GLOBAL EDUCATION INC.
AMD ADVANCED MICRO DEVICES INC.
AVGO BROADCOM INC.
DELL DELL TECHNOLOGIES INC CLASS C
BSIG BRIGHTSPHERE INVESTMENT GROUP INC.
ARCH ARCH RESOURCES INC. CLASS A
ORIC ORIC PHARMACEUTICALS
VRT VERTIV HOLDINGS CO (A)
MRVL MARVELL TECHNOLOGY INC
NPCE NEUROPACE INC
EWTX ONTO INNOVATION INC.
IRON EDGEWISE THERAPEUTICS INC
DISC MEDICINE INC
- Jonathan Moreland
FDX FEDEX CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
SNCR SYNCHRONOSS TECHNOLOGIES
AXR INC.
KSM AMREP
VTN DWS STRATEGIC MUNICIPAL INCOME TRUST
VOXX INVESCO TRUST FOR INVESTMENT G
ENX AUDIOVOX CORPORATION
VPV EATON VANCE NEW YORK MUNICIPAL BOND FUND
INVESCO PA VALUE MUNI INC TST
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference: 42nd Annual J.P. Morgan Healthcare Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate overview on Thursday, ...
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Heal...
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, at 9:45 am PT. The live presentation will be webcast and may be accessed from the Inve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.